<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    KemPharm, Inc.

    KemPharm, Inc.

    KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...

    KemPharmÂŽ is a clinical-stage specialty pharma...

    Filing Type:    PU
    Daiichi Sankyo Co., Ltd.

    Daiichi Sankyo Co., Ltd.

    Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...

    Founded on September 28, 2005 through the merge...

    Filing Type:    PU
    Fisher Wallace Laboratories, Inc.

    Fisher Wallace Laboratories, Inc.

    Fisher Wallace manufactures and markets wearable medical devices for the treatment...

    Fisher Wallace manufactures and markets wearabl...

    Amount Raised:    $670,653.00
    Fundraising Status:    EC
    Filing Type:    CF
    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...

    Corbus Pharmaceuticals Holdings, Inc. is a Phas...

    Filing Type:    PU
    Cara Therapeutics, Inc.

    Cara Therapeutics, Inc.

    Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...

    Cara Therapeutics is a clinical-stage biopharma...

    Filing Type:    PU
    Esperion Therapeutics, Inc.

    Esperion Therapeutics, Inc.

    Esperion is a pharmaceutical company passionately committed to developing and comm...

    Esperion is a pharmaceutical company passionate...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Agios Pharmaceuticals, Inc.

    Agios Pharmaceuticals, Inc.

    Agios is a biopharmaceutical company passionately committed to applying our scient...

    Agios is a biopharmaceutical company passionate...

    Filing Type:    PU
    Kura Oncology, Inc.

    Kura Oncology, Inc.

    We are a clinical-stage biopharmaceutical company committed to realizing the promi...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.